Global Autism Therapy Market, By Age Group (Child, Adult), Type (Asperger Syndrome, Pervasive Developmental Disorder, Autistic Disorder), Treatment Type (ABA, Hyperbaric Oxygen Therapy, Chelation Therapy, Oxytocin Therapy, Others), Drug (Anticonvulsants, Antipsychotics, Insomnia Drugs, SSRIs, Stimulants, Others), Distribution Channel (Hospital & Clinics, Retail Pharmacies, Online Pharmacies) – Industry Trends and Forecast to 2030.
Autism Therapy Market Analysis and Size
The growing incidence of autism and pervasive developmental disorder (PDD) is essential to escalate market growth. Huge research studies performed by organizations to assess the safety and efficiency of drugs in patients with ASD are anticipated to boost market growth. The stimulants segment dominated the market with a huge revenue share due to the wide availability and ease of accessibility of drugs to patients.
Data Bridge Market Research analyses that the autism therapy market, which was USD 2.05 billion in 2022, would rise to USD 3.42 billion by 2030 and is expected to undergo a CAGR of 6.60% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Autism Therapy Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Age Group (Child, Adult), Type (Asperger Syndrome, Pervasive Developmental Disorder, Autistic Disorder), Treatment Type (ABA, Hyperbaric Oxygen Therapy, Chelation Therapy, Oxytocin Therapy, Others), Drug (Anticonvulsants, Antipsychotics, Insomnia Drugs, SSRIs, Stimulants, Others), Distribution Channel (Hospital & Clinics, Retail Pharmacies, Online Pharmacies)
|
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc.(U.S.), Lilly (U.S.), Abbvie, Inc (U.S.), Merck & Co., Inc (U.S.)., Teva Pharmaceutical Industries Ltd.(Israel), Novartis AG (Switzerland), Johnson & Johnson Services, Inc (U.S.)., Hopebridge, LLC (U.S.)., Bristol-Myers Squibb Company (U.S.), Otsuka America Pharmaceutical, Inc (Japan)., Curemark, LLC (U.S.)., Sosei Group Corporation (Japan), Sun Pharmaceutical Industries Ltd. (India), Mylan N.V. (U.S.)., Endo International plc (Ireland), and F. Hoffmann-La Roche Ltd (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
Autism therapies are the type of therapies that are applied in autistic children or adults to improve or enhance their condition. Different therapies include speech-language therapy, behavior therapy, play-based therapy, occupational therapy, physical therapy, and nutritional therapy. This neurological disorder is related to several disabilities, such as challenges with the individual's behavior or lack of social skills. The diagnosis of autism can be made from a very early age, but the cause is still unknown.
Global Autism Therapy Market Dynamics
Drivers
- Increasing Rate of Autistic Population
The increasing incidence of the autistic population is boosting the market's growth. For instance, France and Portugal have the lowest rates of autism in the world, with approximately 0.69% and 0.71%, respectively, as per the research published by Health Data Exchange. In 2021, the CDC stated that nearly 1 in 44 children in the U.S. is diagnosed with an autism spectrum disorder (ASD). Thus, this increasing prevalence demands high adoption of therapies, boosting the market growth.
- Increasing R&D Activities Associated with Autism Therapy
Huge research studies performed by organizations to assess the safety and efficacy of drugs in patients with ASD are anticipated to drive the market. The positive outcomes of these studies lead to new growth opportunities for the market. For instance, Stalicla completed phase 1b trials of precision medicine candidate STP1 and witnessed positive results with symptom improvement in patients with ASD in 2022. Therefore, the effective completion of the trial and following product approvals are estimated to drive the market. Thus, this factor boosts market growth.
Opportunities
- Increasing Demand for Stimulants
The increasing demand for stimulants is boosting the growth of the market. Adderall, Focalin, Vyvanse, Dexedrine, and Ritalin are some stimulants approved by the U.S. FDA for treating patients who have autism. These drugs improve patient behavior by 80% when administered properly to patients. Therefore, growing efficiency related to the stimulants may attract a new target population and boost market growth.
- Increasing Product Launches
A growing number of product launches associated with autism therapy boost market growth. For instance, the FDA granted fast-track designation to Curemark's CM-AT specified for ASD in 3-8 years old children in 2022. Furthermore, Indian researchers developed the 6BIO compound in 2021, which has shown the potential to enhance daily activities in the pre-clinical investigation of patients with an autism spectrum disorder. Thus, this factor boosts market growth.
Restraints/Challenges
- High Cost of Autism therapy
The huge cost of various autistic therapies and their repeated sessions impede the market growth. Therapies such as behavioral, educational, developmental, and proper counseling sessions offer a huge cost range. For many potential users, particularly those with low financial means, the cost of these therapies may be a big factor. Therefore, these factors hamper the market growth.
This autism therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the autism therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In 2022, Bened Life launched the first gut-brain medical probiotic named Neuralli. Neuralli is designed to raise awareness about mental health and support neurological conditions including but not limited to Parkinson's disease (P.D.) and autism spectrum disorder (ASD).
- In 2022, STALICLA, a Swiss clinical-stage biotech company leading omics-based drug development for patients with neurodevelopmental disorders (NDDs), stated the highly successful completion of the phase 1b trials for its lead drug candidate STP1.
Global Autism Therapy Market Scope
The autism therapy market is segmented on the basis of age group, type, treatment type, drug and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Age Group
- Child
- Adult
Type
- Asperger Syndrome
- Pervasive Developmental Disorder
- Autistic Disorder
Treatment Type
- ABA
- Hyperbaric Oxygen Therapy
- Chelation Therapy
- Oxytocin Therapy
- Others
Drug
- Anticonvulsants
- Carbamazepine
- Oxcarbazepine
- Lamotrigine
- Antipsychotics
- Amisulpride.
- Aripiprazole.
- Asenapine
- Insomnia Drugs
- Triazolam
- Estazolam
- SSRIs
- Citalopram
- Dapoxetine
- Escitalopram
- Stimulants
- Others
Distribution Channel
- Hospital & Clinics
- Retail Pharmacies
- Online Pharmacies
Autism Therapy Market Regional Analysis/Insights
The autism therapy market is analyzed and market size insights and trends are provided by age group, type, treatment type, drug and distribution channel as referenced above.
The countries covered in the autism therapy market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the autism therapy market due to increasing R&D activities and the launching several new products through mergers and strategic partnerships in this region. Also, the increasing awareness about the availability of numerous therapies to treat patients with autism spectrum disorders in this region.
Asia-Pacific is expected to witness significant growth due to the wide presence of major market players and strategic initiatives undertaken by them to develop and commercialize several new products to treat patients. For instance, Teijin Pharma and Hamamatsu Medical University confirmed the safety, efficiency, and tolerability of oxytocin nasal spray for treating patients with an autism spectrum disorder in 2022.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The autism therapy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for autism therapy market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the autism therapy market. The data is available for historic period 2011-2021.
Competitive Landscape and Autism Therapy Market Share Analysis
The autism therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to autism therapy market.
Some of the major players operating in the autism therapy market are:
- Pfizer Inc. (U.S.)
- Lilly (U.S.)
- Abbvie, Inc (U.S.)
- Merck & Co., Inc (U.S.).
- Teva Pharmaceutical Industries Ltd.(Israel)
- Novartis AG (Switzerland)
- Johnson & Johnson Services, Inc (U.S.).
- Hopebridge, LLC (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Otsuka America Pharmaceutical, Inc (Japan)
- Curemark, LLC (U.S.).
- Sosei Group Corporation (Japan)
- Sun Pharmaceutical Industries Ltd.(India)
- Mylan N.V. (U.S.).
- Endo International plc (Ireland)
- F. Hoffmann-La Roche Ltd (Switzerland)
SKU-